CBD-treated CR NSCLC cells had significantly lower numbers of CD44+ and CD133+ cells (H460-CR; 41.73% vs. A549-CR; 81.70%) in comparison to VC controls (H460; 91% vs. A549; 95.877%) (Figure 4C,D). The gene discussed is CD44; the disease is non-small cell lung carcinoma.